Ibogaine neuroregeneration · evidence status
Research Tracker
A living, source-led view of study records, milestones, and the limits of current claims about ibogaine-associated neuroplasticity and neuroregeneration.
Status labels describe the public record, not a clinical conclusion.
How to use this page
Start with the study record, not the headline
This tracker follows public registrations, published papers, preprints, and formal regulatory updates where they can be verified. It separates a biological hypothesis from an endpoint measured in people, and it notes when an entry cannot yet answer a neuroregeneration question.
For broader framing on ibogaine-associated brain research, the site’s evidence-first overview of the topic provides context without treating preliminary signals as settled conclusions. The term neuroplasticity itself covers many possible changes in nervous-system structure or function; it is not interchangeable with demonstrated neural repair.
Annotation: a completed trial, a mechanistic finding, or a registered protocol can each be important, but none alone establishes a treatment outcome or makes an unapproved intervention appropriate.
Current record types
What belongs in a transparent tracker
Public records are uneven. Some studies have a trial identifier and detailed endpoint fields; some have a paper but no accessible protocol; others are announced without enough primary documentation to assess. The cards below state that difference plainly rather than filling gaps with assumptions.
Registered clinical studies
Registry entries can document study type, sponsor or institution, primary outcomes, and estimated dates when investigators make those fields public.
- Trial identifier
- Record the NCT number or other registry identifier exactly as listed.
- Primary endpoints
- Quote the registry field; do not recast a symptom or safety endpoint as neural regeneration.
- Completion
- Use the public estimated or actual date, retaining the registry’s status language.
Searches should begin with the ClinicalTrials.gov study registry, while recognizing that registry information may be updated after a study’s initial posting.
Preclinical and mechanistic work
Cell, animal, and molecular studies may be relevant to a neuroplasticity hypothesis. They do not by themselves show that the same process occurs, or is beneficial, in humans.
- Study type
- State the model and whether findings are behavioral, cellular, molecular, imaging-based, or another category.
- Protocol or preprint
- Link a public primary source only when one is available.
- Interpretation
- Keep the conclusion within the model studied and note any gap to human evidence.
The PubMed literature database helps trace a paper’s publication record, related articles, and indexing terms without treating citation volume as proof.
Milestones and formal notices
Regulatory events can affect how research is conducted or discussed, but they are not a substitute for peer-reviewed outcome data.
- Sponsor or institution
- Name only the organization shown in a public trial, publication, or formal notice.
- Evidence boundary
- Separate authorization to study from authorization to market or prescribe.
- Safety relevance
- Flag eligibility criteria, monitoring, and adverse-event reporting as part of the interpretation.
The FDA drug development and approval process explains why investigational research and approval are distinct stages.
Annotated timeline
Signals, studies, and what dates can mean
A timeline is useful only when the annotation keeps pace with the evidence. Early preclinical observations can motivate later work; they cannot settle whether a neuroregeneration hypothesis applies to people. The entries below are deliberately framed as research milestones rather than efficacy claims.
-
Early preclinical signals
Mechanistic questions take shape
Laboratory work raises questions about ibogaine-related signaling and neural adaptation. These observations belong to a preclinical evidence category and should be read within the limits of their models.
-
2024
Public discussion intensifies around study design
Interest in psychedelic-adjacent neuroplasticity research increases attention to endpoints, controls, follow-up, and adverse-event reporting. A well-described protocol remains different from a completed result.
-
2026
Tracker checkpoint for new records
This marker denotes an ongoing review period: confirm identifiers, completion dates, linked protocols, and publication status before describing any study as evidence of a clinical neuroregeneration outcome.
Update log
How tracker changes are handled
Last checked: October 8, 2026. Each review pass compares public registry status, available publication records, and formal notices. When the public record is incomplete, the entry remains limited to what can be sourced rather than inferred.
Questions about how claims are weighed can be read alongside the site’s evidence review approach. The purpose is research transparency: not to promote access to unapproved treatments, and not to turn early findings into personal medical guidance.
Update rules
- Keep identifiers, sponsor names, and endpoint wording tied to a public primary record.
- Mark estimated completion dates as estimates unless a registry reports an actual completion date.
- Note when a protocol, preprint, results table, or publication is not publicly available.
- Do not infer a clinical result from recruitment status, a press item, or a mechanistic hypothesis.
Safety context stays attached
- Read eligibility and exclusion criteria before generalizing any finding.
- Keep cardiac monitoring and adverse-event reporting visible in study interpretation.
- Distinguish research participation rules from real-world safety or access claims.
- Use the site’s cardiac-risk context when considering why a study’s safety design matters.
“A transparent tracker can say ‘not yet known’ without making the underlying question less important.”
For people looking specifically at alcohol-related research questions, the available material on ibogaine and extreme alcoholism should likewise be read as context, not as evidence that an unapproved treatment is safe, effective, or appropriate.
Questions about interpretation
Tracker notes
Does a trial listing prove that an intervention works?
No. A registration record describes a planned, recruiting, active, completed, or otherwise recorded study. It does not by itself establish safety, effectiveness, or a neuroregeneration outcome.
Why are neuroplasticity and neuroregeneration kept separate here?
Neuroplasticity is a broad term for changes in nervous-system organization or function. Neuroregeneration is a stronger claim involving restoration or regrowth. A study may explore one without demonstrating the other in people.
How should cardiac safety affect interpretation of this tracker?
Cardiac safety remains a central context for ibogaine research. Research entries should be read alongside study eligibility criteria, monitoring plans, adverse-event reporting, and regulatory status rather than as access guidance.